|Bid||245.10 x 243000|
|Ask||245.20 x 260500|
|Day's range||238.20 - 245.90|
|52-week range||218.30 - 273.00|
|PE ratio (TTM)||21.76|
|Earnings date||1 Feb 2018|
|Forward dividend & yield||8.22 (3.22%)|
|1y target est||270.86|
The question for patients with early-stage HER2+ breast cancer is if it’s worth taking a treatment (Nerlynx) that lowers the risk of distant recurrence by less than 2% at 5 years, and which has not yet been studied over the long term.
It’s safer to invest in, cheap and offers a huge potential in continued earnings recovery. As the big investment banks start to look ahead to 2018, UBS has already picked one of its favorites and the needle ...